144 related articles for article (PubMed ID: 3175048)
1. Enhancement of radiation-induced tumor cell killing by the hypoxic cell toxin SR 4233.
Zeman EM; Hirst VK; Lemmon MJ; Brown JM
Radiother Oncol; 1988 Jul; 12(3):209-18. PubMed ID: 3175048
[TBL] [Abstract][Full Text] [Related]
2. SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.
Zeman EM; Brown JM; Lemmon MJ; Hirst VK; Lee WW
Int J Radiat Oncol Biol Phys; 1986 Jul; 12(7):1239-42. PubMed ID: 3744945
[TBL] [Abstract][Full Text] [Related]
3. Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo.
Herman TS; Teicher BA; Coleman CN
Cancer Res; 1990 Aug; 50(16):5055-9. PubMed ID: 2379171
[TBL] [Abstract][Full Text] [Related]
4. SR 4233: a tumor specific radiosensitizer active in fractionated radiation regimes.
Brown JM; Lemmon MJ
Radiother Oncol; 1991; 20 Suppl 1():151-6. PubMed ID: 2020764
[TBL] [Abstract][Full Text] [Related]
5. Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors.
Brown JM; Lemmon MJ
Cancer Res; 1990 Dec; 50(24):7745-9. PubMed ID: 2253217
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
Minchinton AI; Brown JM
Br J Cancer; 1992 Dec; 66(6):1053-8. PubMed ID: 1457345
[TBL] [Abstract][Full Text] [Related]
7. Aerobic radiosensitization by SR 4233 in vitro and in vivo.
Zeman EM; Lemmon MJ; Brown JM
Int J Radiat Oncol Biol Phys; 1990 Jan; 18(1):125-32. PubMed ID: 2298615
[TBL] [Abstract][Full Text] [Related]
8. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
Siim BG; Pruijn FB; Sturman JR; Hogg A; Hay MP; Brown JM; Wilson WR
Cancer Res; 2004 Jan; 64(2):736-42. PubMed ID: 14744792
[TBL] [Abstract][Full Text] [Related]
9. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
Brown JM
Br J Cancer; 1993 Jun; 67(6):1163-70. PubMed ID: 8512801
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the enhancement of tumor responses to fractionated irradiation by SR 4233 (tirapazamine) and by nicotinamide with carbogen.
Dorie MJ; Menke D; Brown JM
Int J Radiat Oncol Biol Phys; 1994 Jan; 28(1):145-50. PubMed ID: 8270435
[TBL] [Abstract][Full Text] [Related]
11. Tumor hypoxia can be exploited to preferentially sensitize tumors to fractionated irradiation.
Brown JM; Lemmon MJ
Int J Radiat Oncol Biol Phys; 1991 Mar; 20(3):457-61. PubMed ID: 1995531
[TBL] [Abstract][Full Text] [Related]
12. Comparison of in vivo efficacy of hypoxic cytotoxin tirapazamine and hypoxic cell radiosensitizer KU-2285 in combination with single and fractionated irradiation.
Shibata T; Shibamoto Y; Sasai K; Oya N; Murata R; Takagi T; Hiraoka M; Abe M
Jpn J Cancer Res; 1996 Jan; 87(1):98-104. PubMed ID: 8609056
[TBL] [Abstract][Full Text] [Related]
13. The effect of the hypoxic cell drug SR-4233 alone or combined with the ionizing radiations on two human tumor cell lines having different radiosensitivity.
Lambin P; Guichard M; Chavaudra N; Malaise EP
Radiother Oncol; 1992 Jul; 24(3):201-4. PubMed ID: 1410575
[TBL] [Abstract][Full Text] [Related]
14. Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines.
Zhang M; Stevens G
Melanoma Res; 1998 Dec; 8(6):510-5. PubMed ID: 9918413
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and bioreductive metabolism of the novel benzotriazine di-N-oxide hypoxic cell cytotoxin tirapazamine (WIN 59075; SR 4233; NSC 130181) in mice.
Walton MI; Workman P
J Pharmacol Exp Ther; 1993 May; 265(2):938-47. PubMed ID: 8496834
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
Monge A; Palop JA; López de Ceráin A; Senador V; Martínez-Crespo FJ; Sainz Y; Narro S; García E; de Miguel C; González M
J Med Chem; 1995 May; 38(10):1786-92. PubMed ID: 7752202
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for benzotriazine di-N-oxides.
Zeman EM; Baker MA; Lemmon MJ; Pearson CI; Adams JA; Brown JM; Lee WW; Tracy M
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):977-81. PubMed ID: 2703405
[TBL] [Abstract][Full Text] [Related]
18. Pre- and post-irradiation radiosensitization by SR 4233.
Zeman EM; Brown JM
Int J Radiat Oncol Biol Phys; 1989 Apr; 16(4):967-71. PubMed ID: 2703404
[TBL] [Abstract][Full Text] [Related]
19. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
Hicks KO; Siim BG; Pruijn FB; Wilson WR
Radiat Res; 2004 Jun; 161(6):656-66. PubMed ID: 15161354
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a CHO cell line resistant to killing by the hypoxic cell cytotoxin SR 4233.
Giaccia AJ; Biedermann KA; Tosto LM; Minchinton AI; Kovacs MS; Brown JM
Int J Radiat Oncol Biol Phys; 1992; 22(4):681-4. PubMed ID: 1544836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
